Cabozantinib over sunitinib for metastatic renal cell carcinoma

Bookmark and Share
Published: 10 Oct 2016
Views: 1769
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Dr Choueiri presents, at a press conference at ESMO 2016, results of the CABOSUN comparitive trial, which assessed outcomes of patients with metastatic rencal cell carcinoma receiving cabozantinib versus sunitnib.

Both drugs are tyrosine kinase inhibitors (TKIs) targeting VEGFR, however cabozantinib has additional actions in inhibition of MET and AXL.

He describes the results, which demonstrate improved progression free survival in the cabozantinib arm, and considers its progression towards wider adoption and approval.

Dr Choueiri spoke further with ecancer about these findings here, and details are available in the news coverage here.